235 related articles for article (PubMed ID: 10924275)
1. CLN3 protein regulates lysosomal pH and alters intracellular processing of Alzheimer's amyloid-beta protein precursor and cathepsin D in human cells.
Golabek AA; Kida E; Walus M; Kaczmarski W; Michalewski M; Wisniewski KE
Mol Genet Metab; 2000 Jul; 70(3):203-13. PubMed ID: 10924275
[TBL] [Abstract][Full Text] [Related]
2. Intracellular trafficking of the JNCL protein CLN3.
Haskell RE; Derksen TA; Davidson BL
Mol Genet Metab; 1999 Apr; 66(4):253-60. PubMed ID: 10191111
[TBL] [Abstract][Full Text] [Related]
3. Analysis of intracellular distribution and trafficking of the CLN3 protein in fusion with the green fluorescent protein in vitro.
Kida E; Kaczmarski W; Golabek AA; Kaczmarski A; Michalewski M; Wisniewski KE
Mol Genet Metab; 1999 Apr; 66(4):265-71. PubMed ID: 10191113
[TBL] [Abstract][Full Text] [Related]
4. Defective lysosomal arginine transport in juvenile Batten disease.
Ramirez-Montealegre D; Pearce DA
Hum Mol Genet; 2005 Dec; 14(23):3759-73. PubMed ID: 16251196
[TBL] [Abstract][Full Text] [Related]
5. Altered arginine metabolism in the central nervous system (CNS) of the Cln3-/- mouse model of juvenile Batten disease.
Chan CH; Ramirez-Montealegre D; Pearce DA
Neuropathol Appl Neurobiol; 2009 Apr; 35(2):189-207. PubMed ID: 19284480
[TBL] [Abstract][Full Text] [Related]
6. Role of the Lysosomal Membrane Protein, CLN3, in the Regulation of Cathepsin D Activity.
Cárcel-Trullols J; Kovács AD; Pearce DA
J Cell Biochem; 2017 Nov; 118(11):3883-3890. PubMed ID: 28390177
[TBL] [Abstract][Full Text] [Related]
7. Evidence for phosphorylation of CLN3 protein associated with Batten disease.
Michalewski MP; Kaczmarski W; Golabek AA; Kida E; Kaczmarski A; Wisniewski KE
Biochem Biophys Res Commun; 1998 Dec; 253(2):458-62. PubMed ID: 9878558
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of lysosomal acid phosphatase in CLN3-defective cells and mouse brain tissue.
Pohl S; Mitchison HM; Kohlschütter A; van Diggelen O; Braulke T; Storch S
J Neurochem; 2007 Dec; 103(6):2177-88. PubMed ID: 17868323
[TBL] [Abstract][Full Text] [Related]
9. CLN3 disease process: missense point mutations and protein depletion in vitro.
Golabek AA; Kida E; Walus M; Kaczmarski W; Wujek P; Wisniewski KE
Eur J Paediatr Neurol; 2001; 5 Suppl A():81-8. PubMed ID: 11589014
[TBL] [Abstract][Full Text] [Related]
10. Retinal pathology and function in a Cln3 knockout mouse model of juvenile Neuronal Ceroid Lipofuscinosis (batten disease).
Seigel GM; Lotery A; Kummer A; Bernard DJ; Greene ND; Turmaine M; Derksen T; Nussbaum RL; Davidson B; Wagner J; Mitchison HM
Mol Cell Neurosci; 2002 Apr; 19(4):515-27. PubMed ID: 11988019
[TBL] [Abstract][Full Text] [Related]
11. Novel interactions of CLN3 protein link Batten disease to dysregulation of fodrin-Na+, K+ ATPase complex.
Uusi-Rauva K; Luiro K; Tanhuanpää K; Kopra O; Martín-Vasallo P; Kyttälä A; Jalanko A
Exp Cell Res; 2008 Sep; 314(15):2895-905. PubMed ID: 18621045
[TBL] [Abstract][Full Text] [Related]
12. Novel CLN3 mutation predicted to cause complete loss of protein function does not modify the classical JNCL phenotype.
Kwon JM; Rothberg PG; Leman AR; Weimer JM; Mink JW; Pearce DA
Neurosci Lett; 2005 Oct; 387(2):111-4. PubMed ID: 16087292
[TBL] [Abstract][Full Text] [Related]
13. Expression studies of CLN3 protein (battenin) in fusion with the green fluorescent protein in mammalian cells in vitro.
Golabek AA; Kaczmarski W; Kida E; Kaczmarski A; Michalewski MP; Wisniewski KE
Mol Genet Metab; 1999 Apr; 66(4):277-82. PubMed ID: 10191115
[TBL] [Abstract][Full Text] [Related]
14. Localization and processing of CLN3, the protein associated to Batten disease: where is it and what does it do?
Pearce DA
J Neurosci Res; 2000 Jan; 59(1):19-23. PubMed ID: 10658181
[TBL] [Abstract][Full Text] [Related]
15. btn1, the Schizosaccharomyces pombe homologue of the human Batten disease gene CLN3, regulates vacuole homeostasis.
Gachet Y; Codlin S; Hyams JS; Mole SE
J Cell Sci; 2005 Dec; 118(Pt 23):5525-36. PubMed ID: 16291725
[TBL] [Abstract][Full Text] [Related]
16. CLN3p impacts galactosylceramide transport, raft morphology, and lipid content.
Rusyn E; Mousallem T; Persaud-Sawin DA; Miller S; Boustany RM
Pediatr Res; 2008 Jun; 63(6):625-31. PubMed ID: 18317235
[TBL] [Abstract][Full Text] [Related]
17. The CLN3 gene is a novel molecular target for cancer drug discovery.
Rylova SN; Amalfitano A; Persaud-Sawin DA; Guo WX; Chang J; Jansen PJ; Proia AD; Boustany RM
Cancer Res; 2002 Feb; 62(3):801-8. PubMed ID: 11830536
[TBL] [Abstract][Full Text] [Related]
18. Action of BTN1, the yeast orthologue of the gene mutated in Batten disease.
Pearce DA; Ferea T; Nosel SA; Das B; Sherman F
Nat Genet; 1999 May; 22(1):55-8. PubMed ID: 10319861
[TBL] [Abstract][Full Text] [Related]
19. Protracted course of juvenile ceroid lipofuscinosis associated with a novel CLN3 mutation (p.Y199X).
Sarpong A; Schottmann G; Rüther K; Stoltenburg G; Kohlschütter A; Hübner C; Schuelke M
Clin Genet; 2009 Jul; 76(1):38-45. PubMed ID: 19489875
[TBL] [Abstract][Full Text] [Related]
20. Tissue expression and subcellular localization of CLN3, the Batten disease protein.
Margraf LR; Boriack RL; Routheut AA; Cuppen I; Alhilali L; Bennett CJ; Bennett MJ
Mol Genet Metab; 1999 Apr; 66(4):283-9. PubMed ID: 10191116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
